Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

BACKGROUND: Asparagine–glycine–arginine–human tumour necrosis factor (NGR–hTNF) is a vascular targeting agent exploiting a tumour-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13, overexpressed on tumour blood vessels. Significant preclinical synergy was shown between low doses o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gregorc, V, Santoro, A, Bennicelli, E, Punt, C J A, Citterio, G, Timmer-Bonte, J N H, Caligaris Cappio, F, Lambiase, A, Bordignon, C, van Herpen, C M L
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2009
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720203/
https://ncbi.nlm.nih.gov/pubmed/19568235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605162
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars